Headinvest LLC Acquires 698 Shares of Pfizer Inc. (NYSE:PFE)

Headinvest LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,439 shares of the biopharmaceutical company’s stock after acquiring an additional 698 shares during the quarter. Headinvest LLC’s holdings in Pfizer were worth $794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Mirador Capital Partners LP raised its stake in Pfizer by 7.6% during the 2nd quarter. Mirador Capital Partners LP now owns 9,742 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 691 shares during the period. Artemis Investment Management LLP purchased a new stake in shares of Pfizer in the second quarter worth $10,063,000. AHL Investment Management Inc. raised its position in shares of Pfizer by 1.3% during the 2nd quarter. AHL Investment Management Inc. now owns 74,103 shares of the biopharmaceutical company’s stock valued at $2,073,000 after purchasing an additional 936 shares during the period. Ballast Inc. lifted its stake in shares of Pfizer by 24.2% during the 2nd quarter. Ballast Inc. now owns 27,248 shares of the biopharmaceutical company’s stock valued at $762,000 after buying an additional 5,318 shares in the last quarter. Finally, Peoples Bank KS boosted its holdings in Pfizer by 8.1% in the 2nd quarter. Peoples Bank KS now owns 43,987 shares of the biopharmaceutical company’s stock worth $1,230,000 after buying an additional 3,300 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $25.73 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company’s 50-day moving average price is $27.47 and its 200-day moving average price is $28.38. The company has a market cap of $145.81 billion, a PE ratio of 34.77, a price-to-earnings-growth ratio of 0.68 and a beta of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.17) earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were given a $0.42 dividend. The ex-dividend date of this dividend was Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.53%. Pfizer’s dividend payout ratio is presently 227.03%.

Insiders Place Their Bets

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Citigroup initiated coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.